The University of Queensland
$1.2M has been awarded to establish the ACRF Facility for Targeted Radiometals in Cancer at The University of Queensland’s Centre for Advanced Imaging.
An Australian-first facility for the discovery, development and clinical translation of novel alpha particle-based cancer therapeutics, with the aim of unlocking the cancer-curing potential of targeted alpha therapy. These precision medicines have the potential for greater cancer-killing effect with less damage to healthy tissue.
Professor David Reutens, Director of The University of Queensland’s Centre for Advanced Imaging, “ACRF funding provides critical equipment to complete the research pathway from synthesis of novel agents through to clinical studies and patient therapy, enabling researchers to unlock the cancer-curing potential of targeted alpha therapy. The new facility will complement the nation’s most comprehensive suite of preclinical and clinical imaging research instruments at the Centre for Advanced Imaging allowing us to fast-track the development of new cancer therapies.”